Advaxis and Ayala Pharmaceuticals Complete Merger
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and com
Advaxis, Inc. (OTCMKTS:ADXS) Sees Significant Decline in Short Interest
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) was the target of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,400 shares
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Advaxis, Inc. (ADXS)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 19, 2022) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Advaxis, Inc. (
Short Interest in Advaxis, Inc. (OTCMKTS:ADXS) Drops By 27.5%
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 2,900 shares, a dro
Advaxis, Inc. (OTCMKTS:ADXS) Short Interest Down 27.5% in September
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,900 shares, a decrease of 27.5% from the Aug
Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update
Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer Cash runway extends into
Advaxis, Inc. (OTCMKTS:ADXS) Short Interest Update
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 5,600 shares, a growth of 21.7% from the
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level MONMOUTH JUNCTION, N.J., June 29, 2022
Advaxis to Offer 2.5M Shrs and Warrants on Nasdaq, Had Seen Offering 1.47M >ADXS
Advaxis to Offer 2.5M Shrs and Warrants on Nasdaq, Had Seen Offering 1.47M >ADXS
Press Release: Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update
Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogen
Press Release: Advaxis Reports Second Quarter -2-
Stockholders' equity: Series D convertible preferred stock- $0.001 par value; 0 shares authorized, 0 shares issued and outstanding at April 30, 2022 and October 31, 2021.
No Data